Notably, RASSF4 promotes myogenic differentiation (by activating the MST1–Hippo pathway), but in the carcinogenic context of aRMS, due to PAX3-FOXO1-driven activation, instead inhibits the MST1–Hippo pathway, thereby promoting tumorigenesis. The gene discussed is MST1; the disease is alveolar rhabdomyosarcoma.